AstraZeneca's STRIDE Regimen Shows Promising Results in Liver Cancer Trial
AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial
Image: Benzinga
AstraZeneca's Phase 3 EMERALD-3 trial reveals that the STRIDE regimen combined with lenvatinib and TACE significantly enhances progression-free survival in patients with unresectable hepatocellular carcinoma. The trial also indicates a positive trend in overall survival, suggesting the regimen may be a viable treatment option.
- 01The EMERALD-3 trial demonstrated a 30% reduction in disease progression or death for patients using the STRIDE regimen with lenvatinib and TACE compared to TACE alone.
- 02Median progression-free survival for the STRIDE regimen was 13 months, compared to 9.8 months for TACE alone.
- 03The trial's secondary endpoint showed a favorable trend in overall survival for the STRIDE regimen, with median overall survival at 12.9 months versus 8.1 months for TACE.
- 04Ghassan Abou-Alfa, the trial's principal investigator, noted that one-third of patients treated with the dual immunotherapy remained alive and progression-free after two years.
- 05AstraZeneca plans to advance the STRIDE regimen into earlier treatment stages based on these encouraging findings.
Advertisement
In-Article Ad
AstraZeneca Plc has reported promising results from its Phase 3 EMERALD-3 trial, which evaluated the immunotherapy-based STRIDE regimen combined with lenvatinib and transarterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma. The trial indicated a 30% reduction in the risk of disease progression or death for patients receiving the STRIDE regimen with lenvatinib and TACE compared to those treated with TACE alone. The median progression-free survival was 13 months for the STRIDE group, compared to 9.8 months for TACE alone. Additionally, a positive trend in overall survival was observed, with median overall survival at 12.9 months for the STRIDE regimen versus 8.1 months for TACE. The trial's principal investigator, Ghassan Abou-Alfa, emphasized the need for new treatment options, noting that nearly one-third of patients remained alive and progression-free after two years. AstraZeneca aims to further develop the STRIDE regimen for earlier treatment stages, building on these encouraging results.
Advertisement
In-Article Ad
The trial results suggest that the STRIDE regimen could offer a new treatment avenue for patients with liver cancer, potentially improving their quality of life and survival rates.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of the STRIDE regimen for liver cancer treatment?
Connecting to poll...
Read the original article
Visit the source for the complete story.